Evidence map›Paper›PMID 27658486›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Trace Amine-Associated Receptor 1 Regulates Wakefulness and EEG Spectral Composition.

Michael D Schwartz, Sarah W Black, Simon P Fisher, Jeremiah B Palmerston, Stephen R Morairty, Marius C Hoener, Thomas S Kilduff

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 42 citations in OpenAlex.

  1. Effect of TAAR1/5-HTTranslational psychiatry · 2021
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Activation of the nociceptin/orphanin-FQ receptor promotes NREM sleep and EEG slow wave activity.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  20. Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Michael D SchwartzCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA.
Sarah W BlackCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA.
Simon P FisherCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA.
Jeremiah B PalmerstonCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA.
Stephen R MorairtyCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA.
Marius C HoenerNeuroscience, Ophthalmology and Rare Diseases DTA, pRED, Roche Innovation Center Basel, F Hoffmann-La Roche, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6510-6250
Thomas S KilduffCenter for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA.ORCID http://orcid.org/0000-0002-6823-0094
SRI International · USRoche (Switzerland) · CH

Funding

TAAR1 and the Control of WakefulnessR01NS082876 · NINDS · SRI INTERNATIONAL · PI KILDUFF, THOMAS S · 2013 to 2015
$1.3M
TAAR1 agonists as wake-promoting and cognitive-enhancing therapeuticsR21NS085757 · NINDS · SRI INTERNATIONAL · PI KILDUFF, THOMAS S, WALLACE, TANYA L · 2014 to 2015
$951k
TAAR1 Agonists as Narcolepsy TherapeuticsR21NS083639 · NINDS · SRI INTERNATIONAL · PI KILDUFF, THOMAS S · 2013 to 2014
$540k
NINDS NIH HHS R01 NS082876NINDS NIH HHS R21 NS083639NINDS NIH HHS R21 NS085757
6 · The paper itself

Abstract

Trace amine-associated receptor 1 (TAAR1) agonists have been shown to have procognitive, antipsychotic-like, anxiolytic, weight-reducing, glucose-lowering, and wake-promoting activities. We used Taar1 knockout (KO) and overexpressing (OE) mice and TAAR1 agonists to elucidate the role of TAAR1 in sleep/wake. EEG, EMG, body temperature (T

Indexed as

AnimalsBehavior, AnimalBrain WavesCaffeineCentral Nervous System StimulantsMaleMiceMice, KnockoutOxazolesReceptors, G-Protein-CoupledSleep StagesTrace Amine-Associated ReceptorsWakefulness4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamineCaffeineCentral Nervous System StimulantsOxazolesReceptors, G-Protein-CoupledTrace Amine-Associated Receptors

Identifiers

PMID27658486
PMCPMC5437878
OpenAlexW2521597152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.